Since selenium is inversely associated with CAD risk and IL-6 levels among elderly people [77], we indeed demonstrated a therapeutic effect of selenium in mitigating the IL-6 levels by postoperative mononuclear cells, which was consistent with a report stating reduced IL-6 levels upon treatment with selenium, with different formulations, in the ApoE−/− atherosclerosis mouse model [78]. Here, IL6 is linked to atherosclerosis.